BidaskClub upgraded shares of Cardiovascular Systems (NASDAQ:CSII) from a sell rating to a hold rating in a report published on Friday, BidAskClub reports.

CSII has been the subject of a number of other research reports. Lake Street Capital raised their price target on shares of Cardiovascular Systems from $50.00 to $60.00 and gave the company a buy rating in a report on Wednesday, August 7th. Needham & Company LLC reissued a hold rating on shares of Cardiovascular Systems in a report on Wednesday, August 7th. Bank of America lowered shares of Cardiovascular Systems from a buy rating to an underperform rating and set a $42.00 price target for the company. in a report on Thursday, April 11th. They noted that the move was a valuation call. Stifel Nicolaus lowered shares of Cardiovascular Systems from a buy rating to a hold rating and raised their price target for the company from $41.00 to $45.00 in a report on Tuesday, July 16th. They noted that the move was a valuation call. Finally, Zacks Investment Research lowered shares of Cardiovascular Systems from a hold rating to a strong sell rating and set a $47.00 price target for the company. in a report on Thursday, August 8th. Two investment analysts have rated the stock with a sell rating, three have given a hold rating, one has given a buy rating and one has assigned a strong buy rating to the company’s stock. The stock has an average rating of Hold and a consensus target price of $48.50.

Shares of Cardiovascular Systems stock opened at $47.77 on Friday. The company has a debt-to-equity ratio of 0.14, a current ratio of 4.25 and a quick ratio of 3.83. The firm has a 50 day moving average of $44.40. Cardiovascular Systems has a fifty-two week low of $24.84 and a fifty-two week high of $49.37.

Cardiovascular Systems (NASDAQ:CSII) last issued its quarterly earnings results on Tuesday, August 6th. The medical device company reported $0.04 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.04. The business had revenue of $68.23 million during the quarter, compared to analyst estimates of $66.04 million. Cardiovascular Systems had a negative net margin of 0.10% and a negative return on equity of 0.18%. Equities analysts predict that Cardiovascular Systems will post 0.02 earnings per share for the current fiscal year.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Arizona State Retirement System grew its holdings in Cardiovascular Systems by 0.6% during the 2nd quarter. Arizona State Retirement System now owns 54,023 shares of the medical device company’s stock worth $2,319,000 after acquiring an additional 304 shares during the period. Advisor Group Inc. grew its holdings in Cardiovascular Systems by 88.8% during the 2nd quarter. Advisor Group Inc. now owns 655 shares of the medical device company’s stock worth $28,000 after acquiring an additional 308 shares during the period. Altshuler Shaham Ltd acquired a new stake in Cardiovascular Systems during the 2nd quarter worth $28,000. Diversified Trust Co grew its holdings in Cardiovascular Systems by 8.2% during the 2nd quarter. Diversified Trust Co now owns 8,815 shares of the medical device company’s stock worth $378,000 after acquiring an additional 665 shares during the period. Finally, BerganKDV Wealth Management LLC grew its holdings in Cardiovascular Systems by 25.0% during the 2nd quarter. BerganKDV Wealth Management LLC now owns 5,000 shares of the medical device company’s stock worth $215,000 after acquiring an additional 1,000 shares during the period. 92.30% of the stock is owned by hedge funds and other institutional investors.

About Cardiovascular Systems

Cardiovascular Systems, Inc, a medical device company, develops, manufactures, and commercializes various devices to treat vascular and coronary diseases in the United States. The company offers peripheral arterial disease products, including Diamondback 360 Peripheral, Predator 360, Stealth 360 Peripheral Orbital Atherectomy System (OAS), Diamondback 360 60cm Peripheral OAS, Diamondback 360 Low Profile Peripheral, Diamondback 360 1.50 Peripheral, Diamondback 360 2.00 Peripheral, Diamondback 360 200cm Peripheral, and Diamondback 360 180cm Peripheral, which are catheter-based platforms for treating a range of plaque types in leg arteries above and below the knee, including calcified plaque, as well as address various limitations associated with surgical, catheter, and pharmacological treatment alternatives.

See Also: What is the significance of a dead cat bounce?

Receive News & Ratings for Cardiovascular Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardiovascular Systems and related companies with MarketBeat.com's FREE daily email newsletter.